Results 41 to 50 of about 11,480 (212)

Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable Angina [PDF]

, 2003
BACKGROUND: This study was designed to investigate long-term effects of the glycoprotein IIb/IIIa inhibitor abciximab in patients with acute coronary syndrome without ST elevation who were not scheduled for coronary intervention.
Armstrong, P.W. (Paul), Barnathan, E.S. (Elliot), Boersma, H. (Eric), Cooper, J.S. (Jay), James, S.K. (Stefan), Ohman, E.M. (Magnus), Ottervanger, J.P. (Jan Paul), Simoons, M.L. (Maarten), Topol, E.J. (Eric), Wallentin, L.C. (Lars)   +9 more
core   +3 more sources

Soluble CD40 ligand in acute coronary syndromes [PDF]

, 2003
BACKGROUND: CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition ...
Boersma, H. (Eric), Brand, M.J.B.M. (Marcel) van den, Dimmeler, S. (Stefanie), Hamm, C.W. (Christian), Heeschen, C. (Christopher), Simoons, M.L. (Maarten), Zeiher, A.M. (Andreas)   +6 more
core   +1 more source

The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]

Vojnosanitetski Pregled, 2002
Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko, Dinčić Dragan, Obradović Slobodan, Marković Milić, Orozović Vjekoslav   +4 more
doaj   +1 more source

Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study

Cardiovascular Ultrasound, 2012
Background Embolization of atherosclerotic debris from the rupture of a vulnerable atherosclerotic plaque occurs iatrogenically during percutaneous coronary interventions (PCI) and can induce myocardial necrosis.
Kretzschmar Daniel, Jung Christian, Otto Sylvia, Utschig Stephan, Hartmann Michael, Lehmann Thomas, Yilmaz Atilla, Pörner Tudor C, Figulla Hans R, Ferrari Markus   +9 more
doaj   +1 more source

Novel patient-centered approach to facilitate same-day discharge in patients undergoing elective percutaneous coronary intervention [PDF]

, 2018
Background Same‐day discharge ( SDD ) after elective percutaneous coronary intervention is safe, less costly, and preferred by patients, but it is usually performed in low‐risk patients,
Amin, Amit P, Bach, Richard G, Caruso, Mary, Crimmins-Reda, Patricia, Dennis, Brandy, Kulkarni, Hemant, Kurz, Howard I, Lasala, John M, Miller, Samantha, Pendegraft, Marissa, Pierce, Andrew, Rahn, Brandon, Singh, Jasvindar, Sorensen, Katrine, Zajarias, Alan   +14 more
core   +2 more sources

Estudo experimental do uso de um antagonista do receptor da glicoproteína IIb/IIIa das placentas na prevenção de tromboses em microanastomoses vasculares An experimental study on the use of an antagonist of the platelet glycoprotein IIb/IIIa receptor in the prevention of thrombosis in vascular microanastomoses

Acta Ortopédica Brasileira, 2000
O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevenção da trombose nas microanastomoses arteriais em ratos Wistar.
Márcio Issamu Oide
doaj   +1 more source

Biomimetic Cell Membrane‐Coated Scaffolds for Enhanced Tissue Regeneration

Advanced Materials, Volume 37, Issue 40, October 9, 2025.
This review examines the development and use of cell membrane‐coated scaffolds in tissue engineering. Bioinspired phospholipid and glycocalyx coatings enhance anti‐fouling, anti‐thrombogenic, and selective molecular recognition properties. Native cell membrane coatings further support cell‐specific interactions, immune modulation, and reduced bacterial
Carmen Alvarez‐Lorenzo, Alejandro Ramirez‐Romero, Diana Peixoto, Maria Vivero‐Lopez, Isabel Rodríguez‐Moldes, Angel Concheiro   +5 more
wiley   +1 more source

Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis

Clinical and Applied Thrombosis/Hemostasis, 2020
Background: Endovascular therapy and intravenous thrombolysis with recombinant tissue plasminogen activator are the 2 most recommended treatments for acute ischemic stroke (AIS). Glycoprotein (GP) IIb-IIIa inhibitors are short-acting selective reversible
Xiaolin Zhu MD, Genmao Cao MD
doaj   +1 more source

The use of abciximab associated with primary angioplasty for treating acute myocardial infarction

Arquivos Brasileiros de Cardiologia, 2002
OBJECTIVE: To assess the benefit resulting from the use of abciximab associated with primary angioplasty. The following parameters were analyzed in-hospital, at 30 days, and 6 months: (a) flow in the culprit artery; (b) ventricular function; (c) combined
Manuel Lisandro Hernández Brito, Newton F. Stadler de Souza Filho, Álvaro Vieira Moura, Luiz Augusto Lavalle, Rubens Zenobio Darwich, Marisa Leal, Eva Cantalejo Munhoz   +6 more
doaj   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources